JPS6313405B2 - - Google Patents
Info
- Publication number
- JPS6313405B2 JPS6313405B2 JP15986981A JP15986981A JPS6313405B2 JP S6313405 B2 JPS6313405 B2 JP S6313405B2 JP 15986981 A JP15986981 A JP 15986981A JP 15986981 A JP15986981 A JP 15986981A JP S6313405 B2 JPS6313405 B2 JP S6313405B2
- Authority
- JP
- Japan
- Prior art keywords
- cholesterol
- hdl cholesterol
- vitamin
- blood
- content
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired
Links
- 239000003795 chemical substances by application Substances 0.000 claims description 15
- 102000002322 Egg Proteins Human genes 0.000 claims description 12
- 108010000912 Egg Proteins Proteins 0.000 claims description 12
- 235000013345 egg yolk Nutrition 0.000 claims description 12
- 210000002969 egg yolk Anatomy 0.000 claims description 12
- 239000011782 vitamin Substances 0.000 claims 1
- 229940088594 vitamin Drugs 0.000 claims 1
- 229930003231 vitamin Natural products 0.000 claims 1
- 235000013343 vitamin Nutrition 0.000 claims 1
- 150000003722 vitamin derivatives Chemical class 0.000 claims 1
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 74
- 235000012000 cholesterol Nutrition 0.000 description 37
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 30
- 108010010234 HDL Lipoproteins Proteins 0.000 description 28
- 102000015779 HDL Lipoproteins Human genes 0.000 description 28
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 description 15
- 229930003268 Vitamin C Natural products 0.000 description 15
- 235000019154 vitamin C Nutrition 0.000 description 15
- 239000011718 vitamin C Substances 0.000 description 15
- 239000008280 blood Substances 0.000 description 14
- 210000004369 blood Anatomy 0.000 description 14
- 206010003210 Arteriosclerosis Diseases 0.000 description 12
- 208000011775 arteriosclerosis disease Diseases 0.000 description 12
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 8
- 238000008214 LDL Cholesterol Methods 0.000 description 6
- 230000007423 decrease Effects 0.000 description 6
- 108010069201 VLDL Cholesterol Proteins 0.000 description 5
- 208000006011 Stroke Diseases 0.000 description 4
- 238000004108 freeze drying Methods 0.000 description 4
- 238000002156 mixing Methods 0.000 description 4
- 208000010125 myocardial infarction Diseases 0.000 description 4
- 239000002994 raw material Substances 0.000 description 4
- 208000019553 vascular disease Diseases 0.000 description 4
- 239000003814 drug Substances 0.000 description 3
- 239000000203 mixture Substances 0.000 description 3
- 102000004190 Enzymes Human genes 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- 210000004204 blood vessel Anatomy 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 239000004615 ingredient Substances 0.000 description 2
- OYXZMSRRJOYLLO-UHFFFAOYSA-N 7alpha-Hydroxycholesterol Natural products OC1C=C2CC(O)CCC2(C)C2C1C1CCC(C(C)CCCC(C)C)C1(C)CC2 OYXZMSRRJOYLLO-UHFFFAOYSA-N 0.000 description 1
- OYXZMSRRJOYLLO-RVOWOUOISA-N 7alpha-hydroxycholesterol Chemical compound C([C@H]1O)=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 OYXZMSRRJOYLLO-RVOWOUOISA-N 0.000 description 1
- 108010023302 HDL Cholesterol Proteins 0.000 description 1
- 208000031226 Hyperlipidaemia Diseases 0.000 description 1
- 102000004895 Lipoproteins Human genes 0.000 description 1
- 108090001030 Lipoproteins Proteins 0.000 description 1
- 239000003613 bile acid Substances 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 150000001841 cholesterols Chemical class 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 238000004925 denaturation Methods 0.000 description 1
- 230000036425 denaturation Effects 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000000378 dietary effect Effects 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 235000013601 eggs Nutrition 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000013355 food flavoring agent Nutrition 0.000 description 1
- 238000007710 freezing Methods 0.000 description 1
- 230000008014 freezing Effects 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 238000000034 method Methods 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 230000003449 preventive effect Effects 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 238000000859 sublimation Methods 0.000 description 1
- 230000008022 sublimation Effects 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 238000001291 vacuum drying Methods 0.000 description 1
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Description
【発明の詳細な説明】
本発明は抗動脈硬化剤、更に詳細には血中の
HDLコレステロールを上昇させ、抗動脈硬化作
用を促進して脳卒中、心筋硬塞などの血管病に有
効な抗動脈硬化剤に関する。DETAILED DESCRIPTION OF THE INVENTION The present invention provides an anti-arteriosclerotic agent, more specifically an anti-arteriosclerotic agent.
This invention relates to an anti-arteriosclerotic agent that increases HDL cholesterol, promotes anti-arteriosclerotic action, and is effective against vascular diseases such as stroke and myocardial infarction.
脳卒中、心筋硬塞などの血管病は我国において
死因の首位を占めており、これらの疾病はいずれ
も動脈硬化が原因となつて発生することが公知で
ある。故に、上記血管病の予防のため動脈硬化の
防止が予防医学的見地から重要視されている。 Vascular diseases such as stroke and myocardial infarction are the leading cause of death in Japan, and it is known that all of these diseases are caused by arteriosclerosis. Therefore, prevention of arteriosclerosis is considered important from the viewpoint of preventive medicine in order to prevent the above-mentioned vascular diseases.
近時、疫学調査の結果、血中のHDLコレステ
ロール（High Density Lipoproteinコレステロ
ール）の含有量が低くなると動脈硬化が促進さ
れ、脳卒中、心筋硬塞が惹起されることが明らか
となり、このため血中のHDLコレステロールを
上昇させる薬剤が開発されている。ところが公知
のこの種の薬剤は３ケ月間患者に連続投与しても
血中のHDLコレステロールの上昇はわずか10
mg／dl程度であり、動脈硬化指数の減少もわずか
でしかない。 Recent epidemiological studies have revealed that low levels of HDL cholesterol (High Density Lipoprotein cholesterol) in the blood accelerate arteriosclerosis, leading to stroke and myocardial infarction. Drugs that increase HDL cholesterol have been developed. However, even after continuous administration of this type of drug to patients for three months, blood HDL cholesterol levels increased by only 10%.
mg/dl, and the decrease in arteriosclerosis index is only slight.
従つて、本発明の目的は血中のHDLコレステ
ロールを顕著に増大せしめ、動脈硬化指数を減少
し、しかして脳卒中、心筋硬塞などの血管病に極
めて有効な抗動脈硬化剤を提供することにある。 Therefore, an object of the present invention is to provide an anti-arteriosclerotic agent that significantly increases HDL cholesterol in the blood, reduces the arteriosclerotic index, and is extremely effective against vascular diseases such as stroke and myocardial infarction. be.
本発明によれば、卵黄2200重量部（乾燥基準）
とビタミンC1乃至70重量部（乾燥基準）とを主
成分として含有する凍結乾燥物を含むことを特徴
とする抗動脈硬化剤が提供される。 According to the invention, 2200 parts by weight of egg yolk (dry basis)
Provided is an anti-arteriosclerotic agent comprising a freeze-dried product containing as main components 1 to 70 parts by weight of vitamin C (on a dry basis).
以下、本発明を更に詳細に説明する。 The present invention will be explained in more detail below.
コレステロールには前述のHDLコレステロー
ルの他にLDL（Low Density Lrpoprotein）コレ
ステロール及びVLDL（Very Low Density
Lipoprotein）コレステロールが存在することが
知られているが、HDLコレステロールの血中含
量が少なくなるとLDLコレステロール及び
VLDLコレステロールは共に血管壁に沈着する傾
向が大となり、動脈硬化を生じやすくなるが、
HDLコレステロールの血中含量が多いと動脈硬
化は生じないことが判明している。これは、血中
に存在する遊離のLDLコレステロール及び
VLDLコレステロールが血管壁に沈着する前に
HDLコレステロールがこれらを貧食し、貧食し
たHDLコレステロール自体は肝臓に運ばれて分
解されるものと考えられているからである。故
に、HDLコレステロールの血中含量を増大すれ
ば、動脈硬化の予防が可能となるわけである。 In addition to HDL cholesterol mentioned above, cholesterol includes LDL (Low Density Lrpoprotein) cholesterol and VLDL (Very Low Density Lrpoprotein) cholesterol.
It is known that there is cholesterol (Lipoprotein), but when the blood content of HDL cholesterol decreases, LDL cholesterol and
Both VLDL cholesterol has a greater tendency to be deposited on blood vessel walls, making arteriosclerosis more likely to occur.
It has been found that arteriosclerosis does not occur when the blood content of HDL cholesterol is high. This is caused by free LDL cholesterol and
Before VLDL cholesterol is deposited on blood vessel walls
This is because it is thought that HDL cholesterol depletes these substances, and that the depleted HDL cholesterol itself is transported to the liver and broken down. Therefore, by increasing the blood content of HDL cholesterol, it is possible to prevent arteriosclerosis.
一方、本発明の抗動脈硬化剤の原料の一つであ
る卵黄には古くからコレステロールが含まれてい
ることが知られており、動脈硬化の原因となると
の理由で血中脂質含量の高い、所謂高脂血症の患
者の食事療法においては卵の摂取量は制限されて
いた。ところが、今般驚くべきことに卵黄に上記
所定量の範囲でビタミンＣを配合し摂取すると、
血中のHDLコレステロールが顕著に増大し、動
脈硬化指数が減少することが本発明により明らか
となつた。これは、ビタミンＣを卵黄に配合する
ことにより7α−ヒドロキシコレステロールとし
て知られる酵素が活性化され、この酵素の活性化
によりコレステロールの胆汁酸への異化が促進さ
れ、その結果、LDLコレステロール及びLVDL
コレステロールが減少し、HDLコレステロール
の上昇をまねくものと考えられる。 On the other hand, egg yolk, which is one of the raw materials for the anti-arteriosclerotic agent of the present invention, has been known for a long time to contain cholesterol, and it is believed that it causes arteriosclerosis. In the dietary therapy of patients with so-called hyperlipidemia, the amount of egg intake is restricted. However, it is surprising that when vitamin C is added to egg yolk within the above prescribed amount and ingested,
The present invention has revealed that blood HDL cholesterol increases significantly and arteriosclerosis index decreases. This is because vitamin C infused into egg yolk activates an enzyme known as 7α-hydroxycholesterol, which promotes the catabolism of cholesterol into bile acids, resulting in LDL cholesterol and LVDL.
It is thought that this causes a decrease in cholesterol and an increase in HDL cholesterol.
本発明によれば、卵黄2200重量部（乾燥基準）
に対し、ビタミンC1乃至70重量部（乾燥基準）、
好ましくは10乃至40重量部（乾燥基準）を配合す
る。ビタミンＣの配合量が１重量部未満となる
と、HDLコレステロールの血中含量が上昇する
割合よりもLDLコレステロール及びVLDLコレ
ステロールの上昇する割合の方が高くなり、また
動脈硬化指数、すなわち下記の式で示される値が
上昇し本発明の効果が期待できない。 According to the invention, 2200 parts by weight of egg yolk (dry basis)
1 to 70 parts by weight of vitamin C (dry basis),
Preferably, 10 to 40 parts by weight (dry basis) is blended. If the amount of vitamin C added is less than 1 part by weight, the rate of increase in LDL cholesterol and VLDL cholesterol will be higher than the rate of increase in blood content of HDL cholesterol, and the rate of increase in the arteriosclerotic index, that is, according to the formula below, will increase. The indicated value increases and the effect of the present invention cannot be expected.
動脈硬化指数＝（総コレステロール含量−HDLコレステ
ロール含量）÷（HDLコレステロール含量）
一方、ビタミンＣの配合量が70重量部を越える
と、LDLコレステロール及びVLDLコレステロ
ールの血中含量は低下するが、HDLコレステロ
ールの含量も低下してしまい本発明の効果がなく
なつてしまう。故に、ビタミンＣの配合割合は上
記範囲でなければならない。Arteriosclerotic index = (total cholesterol content - HDL cholesterol content) ÷ (HDL cholesterol content) On the other hand, when the amount of vitamin C added exceeds 70 parts by weight, the blood content of LDL cholesterol and VLDL cholesterol decreases, but the HDL cholesterol content decreases. The content of . Therefore, the blending ratio of vitamin C must be within the above range.
本発明によれば、卵黄とビタミンＣとを凍結乾
燥物とする。すなわち、卵黄にビタミンＣを添加
混合し、凍結乾燥することにより卵黄中の蛋白
質、酵素、コレステロール等の成分並びにビタミ
ンＣに変性を生ずることなく乾燥させ、粉末状の
乾燥混合物を得ることができる。必要に応じ、砂
糖、香料等の成分を添加し、摂取しやすくするこ
ともできる。また、凍結乾燥物を経口投与する
際、通常水、湯等に溶解させるが、溶解性を増大
する公知成分を添加することも可能である。ま
た、凍結乾燥は必らずしも、各成分原料を混合
後、行なう必要はなく、各成分原料ごとに凍結乾
燥し、次いで混合することもできる。凍結乾燥は
公知の方法により行なうことができ、たとえば減
圧にするための真空ポンプと、昇華して生じた水
蒸気を氷結収集するコールドトラツプと、原料を
いれるデシケータとを装着した凍結乾燥器を用
い、連続式または回分式により製造することがで
きる。凍結温度は特に限定されないが、通常−70
℃以下に凍結し、乾燥室において通常10-2乃至
10-3mmHg程度の減圧下で真空乾燥を行ない、粉
末状若しくは粒状の凍結乾燥物を得ることができ
る。 According to the present invention, egg yolk and vitamin C are freeze-dried. That is, by adding and mixing vitamin C to egg yolk and freeze-drying it, it is possible to dry the components such as proteins, enzymes, and cholesterol in the egg yolk and vitamin C without causing any denaturation, thereby obtaining a powdery dry mixture. If necessary, ingredients such as sugar and flavoring agents can be added to make it easier to ingest. Furthermore, when the lyophilized product is orally administered, it is usually dissolved in water, hot water, etc., but it is also possible to add known ingredients that increase solubility. Further, freeze-drying does not necessarily have to be carried out after mixing each component raw material, but it is also possible to freeze-dry each component raw material and then mix them. Freeze-drying can be carried out by a known method, for example, using a freeze dryer equipped with a vacuum pump to reduce the pressure, a cold trap to freeze and collect the water vapor generated by sublimation, and a desiccator to put the raw material. , can be produced continuously or batchwise. Freezing temperature is not particularly limited, but usually -70
Freeze below ℃ and store in drying room usually 10 -2 ~
Vacuum drying is performed under reduced pressure of about 10 −3 mmHg to obtain a powdered or granular freeze-dried product.
本発明の抗動脈硬化剤は通常水又は湯に溶解し
て経口投与する。一回の投与量は特に臨界的なも
のではないが、本発明の凍結乾燥物20乃至30ｇ、
好ましくは22乃至26ｇをコツプ１杯程度の水又は
湯に溶かし、１日１回乃至３回程度に飲ませる。 The antiarteriosclerotic agent of the present invention is usually dissolved in water or hot water and administered orally. Although the amount per dose is not particularly critical, 20 to 30 g of the lyophilizate of the present invention,
Preferably, dissolve 22 to 26 g in about a cup of water or hot water and drink it about once to three times a day.
本発明の抗動脈硬化剤を投与すれば、２ケ月で
平均12mm／dlのHDLコレステロールの上昇がみ
られ、動脈硬化指数も大幅に減少することが明ら
かとなり、動脈硬化に非常に有効であることが確
認された。 It has been revealed that when the anti-arteriosclerotic agent of the present invention is administered, HDL cholesterol increases by an average of 12 mm/dl in two months, and the arteriosclerotic index is also significantly reduced, indicating that it is extremely effective against arteriosclerosis. was confirmed.
以下、本発明を実施例につき説明する。 Hereinafter, the present invention will be explained with reference to examples.
実施例
本発明の抗動脈硬化剤22.3ｇをコツプ１杯の湯
に溶かし、朝１回経口投与した患者14名からなる
群と、朝昼夜３回経口投与した患者４名からなる
群と、全く本発明の抗動脈硬化剤を投与しなかつ
た患者20名からなる群（コントロール）とに分
け、毎日投与して３ケ月間血中HDLコレステロ
ールの含量を定期的に測定し、各群の患者１名の
平均HDLコレステロール含量を算出した。添付
図面中、第１図はかようにして算出した平均
HDLコレステロール含量を経時的にプロツトし
て示したグラフである。第１図の線Ａは１日１回
投与の群、線Ｂは１日３回投与の群、線Ｃはコン
トロール群を示す。Example: A group consisting of 14 patients who received 22.3 g of the anti-arteriosclerotic agent of the present invention dissolved in a glass of hot water and orally administered once in the morning, a group consisting of 4 patients who received orally administered three times in the morning, noon and night; The anti-arteriosclerotic agent of the present invention was divided into a group of 20 patients (control) who were not administered the anti-arteriosclerotic agent of the present invention, and the content of HDL cholesterol in the blood was regularly measured for 3 months by administering it daily. The average HDL cholesterol content of the subjects was calculated. In the attached drawings, Figure 1 shows the average calculated in this way.
1 is a graph showing HDL cholesterol content plotted over time. In FIG. 1, line A shows the once-daily administration group, line B shows the three-times-daily administration group, and line C shows the control group.
なお、この実施例に用いた本発明の抗動脈硬化
剤は卵黄22000mgにビタミンC300mgを添加混合し
た後、凍結乾燥させたものである。 The anti-arteriosclerotic agent of the present invention used in this example was prepared by adding and mixing 300 mg of vitamin C to 22,000 mg of egg yolk, and then freeze-drying the mixture.
第１図より明らかなように２週間後には投与し
た群とコントロール群では明らかにHDLコレス
テロール含量が異なつており、１ケ月後には相当
の差があり、２ケ月後には１日３回投与の群（線
Ｂ）とコントロール群（線Ｃ）とでは血液毎dl当
り約50mgのHDLコレステロールの含量の差が見
られた。 As is clear from Figure 1, there was a clear difference in HDL cholesterol content between the administration group and the control group after 2 weeks, and a considerable difference after 1 month, and after 2 months, the HDL cholesterol content was clearly different between the administration group and the control group. (Line B) and the control group (Line C) showed a difference in HDL cholesterol content of approximately 50 mg per dl of blood.
なお、１日１回投与の群の動脈硬化指数を調べ
たところ、投与前では4.75であつたが投与後２ケ
月では3.12に降下し、明らかに本発明の効果が確
認された。（第２図参照。）
比較例
実施例と同様にして血中の平均HDLコレステ
ロール含量を測定した。但し、卵黄22000mgにビ
タミンC9mgを添加混合し、凍結乾燥させたもの
を患者10人に投与した群（第１図中、点線）及び
卵黄22000mgにビタミンC710mgを添加混合し、凍
結乾燥させたものを患者10人に投与した群（第１
図中、１点鎖線）について測定したものである。 When the arteriosclerosis index of the once-daily administration group was examined, it was 4.75 before administration, but it decreased to 3.12 two months after administration, clearly confirming the effectiveness of the present invention. (See Figure 2.) Comparative Example The average HDL cholesterol content in blood was measured in the same manner as in the example. However, a group in which 22,000 mg of egg yolk was mixed with 9 mg of vitamin C and lyophilized was administered to 10 patients (dotted line in Figure 1), and a group in which 22,000 mg of egg yolk was mixed with 710 mg of vitamin C and lyophilized was administered to 10 patients. Group administered to 10 patients (first
In the figure, measurements were taken with respect to the one-dot chain line).
ビタミンC9mgの群ではHDLコレステロールは
わずかに上昇することが判明したが、血中の他の
コレステロールを測定した結果LDLコレステロ
ール及びVLDLコレステロールの上昇が認めら
れ、好ましくないことがわかつた。 HDL cholesterol was found to be slightly elevated in the vitamin C 9 mg group, but when other cholesterols in the blood were measured, LDL cholesterol and VLDL cholesterol were found to be elevated, which was found to be undesirable.
ビタミンC710mgの群ではほとんどHDLコレス
テロールの上昇が認められず効果のないことが判
明した。 In the group receiving 710 mg of vitamin C, almost no increase in HDL cholesterol was observed, indicating that it was ineffective.
第１図は本発明の抗動脈硬化剤の投与効果を示
す血中HDLコレステロール含量の経時的変化を
表わすグラフ、第２図は本発明の抗動脈硬化剤を
投与した場合の動脈硬化指数を示すグラフであ
る。
FIG. 1 is a graph showing changes over time in blood HDL cholesterol content showing the effect of administration of the anti-arteriosclerotic agent of the present invention, and FIG. 2 is a graph showing the arteriosclerosis index when the anti-arteriosclerotic agent of the present invention is administered. It is a graph.
Claims (1)
乃至70重量部（乾燥基準）とを主成分として含有
する冷結乾燥物を含むことを特徴とする抗動脈硬
化剤。1 2200 parts by weight of egg yolk (dry basis) and vitamin C1
70 parts by weight (on a dry basis) of an anti-arteriosclerotic agent characterized by comprising a cooled dry product containing as a main component 70 parts by weight (on a dry basis).
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP15986981A JPS5862117A (en) | 1981-10-07 | 1981-10-07 | Antiarteriosclerotic agent |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP15986981A JPS5862117A (en) | 1981-10-07 | 1981-10-07 | Antiarteriosclerotic agent |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JPS5862117A JPS5862117A (en) | 1983-04-13 |
| JPS6313405B2 true JPS6313405B2 (en) | 1988-03-25 |
Family
ID=15702985
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP15986981A Granted JPS5862117A (en) | 1981-10-07 | 1981-10-07 | Antiarteriosclerotic agent |
Country Status (1)
| Country | Link |
|---|---|
| JP (1) | JPS5862117A (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2020075636A1 (en) | 2018-10-11 | 2020-04-16 | ヤマハ発動機株式会社 | Throttle body assembly for unitary combustion chamber |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2005023239A1 (en) * | 2003-09-05 | 2005-03-17 | Matthias Rath | Pharmaceutical composition comprising i.a. vitamin c, magnesium, green tea extract for retarding cardiovascular diseases |
-
1981
- 1981-10-07 JP JP15986981A patent/JPS5862117A/en active Granted
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2020075636A1 (en) | 2018-10-11 | 2020-04-16 | ヤマハ発動機株式会社 | Throttle body assembly for unitary combustion chamber |
Also Published As
| Publication number | Publication date |
|---|---|
| JPS5862117A (en) | 1983-04-13 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US8679549B2 (en) | Electrolyte purgative | |
| US4348384A (en) | Pharmaceutical composition for oral administration containing coagulation factor VIII or IX | |
| CA2334761C (en) | Composition comprising .beta.-hydroxy-.beta.-methylbutyric acid and at least one amino acid and methods of use | |
| US8158170B2 (en) | Pharmaceutical composition comprising metadoxine and garlic oil for preventing and treating alcohol-induced fatty liver and steatohepatitis | |
| KR950009094B1 (en) | Pharmaceutical compositions containing pyridoxine derivatives for use in the prevention and treatment of hyperlipemia and atherosclerosis | |
| JP3906716B2 (en) | Drugs for abnormal glucose tolerance | |
| JPH01216924A (en) | Therapeutic agent for hepatic disorder | |
| GB2085729A (en) | Pharmaceutical composition for oral administration containing coagulation factor VIII | |
| EP3209293B1 (en) | Dosage regimen of ferric maltol | |
| JP2004105157A (en) | Drinking and eating composition for inhibiting sugar-decomposing enzyme | |
| JPS6313405B2 (en) | ||
| US5567736A (en) | Use of a choline salt to inhibit fatty liver in patients receiving total parenteral nutrition | |
| JP4021505B2 (en) | Antidiabetic drugs and functional foods | |
| JP2004504346A (en) | Use of estramustine phosphate in the treatment of bone metastases | |
| JP2012246308A (en) | Medicinal composition and food and drink for glucose tolerance disorder | |
| CA2521997A1 (en) | Antiobestic agent using hen's egg antibody against digestive enzymes | |
| JPH11158075A (en) | Pancreatic function regulator | |
| JPS6272613A (en) | Preventive and remedy for disseminated intravascular coagulation syndrome | |
| JP2978581B2 (en) | Cholesterol suppressant | |
| Russell et al. | The effect of 2-amino-2-methylpropanol on rat-liver mitochondria | |
| EP0186181A3 (en) | Uses for enprostil | |
| KR950007231B1 (en) | Pharmaceutical formulation for the treatment of liver disease | |
| WO1994005271A1 (en) | Gastrointestinal cancer therapy composition containing dimethylsulphone and dimethylsulphoxide | |
| JPH0132804B2 (en) | ||
| Mak et al. | RENAL HYPERPHOSPHATEMIA |